Morbidly obese patients (BMI >47 kg/m2) and overweight/lean patients (BMI <27 kg/m2)
Evidence of type 1 diabetes and diabetics requiring insulin therapy.
Subjects who have not been weight stable (>2 kg weight change in past 3 months)
Subjects who have been recently active (>30 min of moderate/high intensity exercise, 2 times/week).
Subjects who are smokers or who have quit smoking <5 years ago
Subjects prescribed metformin or have taken metformin within 1 year.
Subjects with abnormal estimated glomerular filtration rate (eGFR).
Hypertriglyceridemic (>400 mg/dl) and hypercholesterolemic (>260 mg/dl) subjects
Hypertensive (>160/100 mmHg)
Subjects currently taking medications that affect heart rate and rhythm (i.e. Ca++ channel blockers, nitrates, alpha- or beta-blockers).
Subjects with a history of significant metabolic, cardiac, congestive heart failure, cerebrovascular, hematological, pulmonary, gastrointestinal, liver, renal, or endocrine disease or cancer that in the investigator's opinion would interfere with or alter the outcome measures, or impact subject safety.
Pregnant (as evidenced by positive pregnancy test) or nursing women
Subjects with contraindications to participation in an exercise training program
Currently taking active weight suppression medication (e.g. phentermine,orlistat, lorcaserin, naltrexone-bupropion in combination, liraglutide, benzephetamine, diethylpropion, phendimetrazine)
Known hypersensitivity to perflutren (contained in Definity)

NCT03355469_exc_T1
Condition
Morbidly obese
NCT03355469_exc_T2
Measurement
BMI
NCT03355469_exc_T3
Value
>47 kg/m2
NCT03355469_exc_T4
Condition
overweight
NCT03355469_exc_T5
Condition
lean
NCT03355469_exc_T6
Measurement
BMI
NCT03355469_exc_T7
Value
<27 kg/m2
NCT03355469_exc_T8
Scope
BMI >47 kg/m2
NCT03355469_exc_T9
Scope
BMI <27 kg/m2
NCT03355469_exc_T10
Scope
overweight/lean
NCT03355469_exc_T11
Scope
overweight/lean patients (BMI <27 kg/m2)
NCT03355469_exc_T12
Condition
type 1 diabetes
NCT03355469_exc_T13
Condition
diabetics
NCT03355469_exc_T14
Qualifier
requiring insulin therapy
NCT03355469_exc_T15
Procedure
insulin therapy
NCT03355469_exc_T16
Drug
insulin
NCT03355469_exc_T17
Negation
not
NCT03355469_exc_T18
Observation
weight stable
NCT03355469_exc_T19
Value
>2 kg
NCT03355469_exc_T20
Measurement
weight change
NCT03355469_exc_T21
Temporal
in past 3 months
NCT03355469_exc_T22
Scope
>2 kg weight change in past 3 months
NCT03355469_exc_T23
Scope
not been weight stable
NCT03355469_exc_T24
Temporal
recently
NCT03355469_exc_T25
Condition
active
NCT03355469_exc_T26
Value
>30 min
NCT03355469_exc_T27
Measurement
moderate/high intensity exercise
NCT03355469_exc_T28
Multiplier
2 times/week
NCT03355469_exc_T29
Scope
>30 min of moderate/high intensity exercise, 2 times/week
NCT03355469_exc_T30
Scope
active (>30 min of moderate/high intensity exercise, 2 times/week)
NCT03355469_exc_T31
Observation
smokers
NCT03355469_exc_T32
Observation
quit smoking
NCT03355469_exc_T33
Temporal
<5 years ago
NCT03355469_exc_T34
Drug
metformin
NCT03355469_exc_T35
Drug
metformin
NCT03355469_exc_T36
Temporal
within 1 year
NCT03355469_exc_T37
Value
abnormal
NCT03355469_exc_T38
Measurement
estimated glomerular filtration rate (eGFR)
NCT03355469_exc_T39
Condition
Hypertriglyceridemic
NCT03355469_exc_T40
Value
>400 mg/dl
NCT03355469_exc_T41
Measurement
Hypertriglyceridemic
NCT03355469_exc_T42
Condition
hypercholesterolemic
NCT03355469_exc_T43
Measurement
cholesterol
NCT03355469_exc_T44
Value
>260 mg/dl
NCT03355469_exc_T45
Condition
Hypertensive
NCT03355469_exc_T46
Value
>160/100 mmHg
NCT03355469_exc_T47
Measurement
Hypertensive
NCT03355469_exc_T48
Drug
medications
NCT03355469_exc_T49
Qualifier
that affect heart rate
NCT03355469_exc_T50
Qualifier
ct heart rate and .e. Ca
NCT03355469_exc_T51
Drug
Ca++ channel blockers
NCT03355469_exc_T52
Drug
nitrates
NCT03355469_exc_T53
Drug
 beta .
Subjec
NCT03355469_exc_T54
Drug
beta-blockers
NCT03355469_exc_T55
Scope
Ca++ channel blockers, nitrates, alpha- or beta-blockers
NCT03355469_exc_T56
Scope
medications that affect heart rate and rhythm
NCT03355469_exc_T57
Observation
history
NCT03355469_exc_T58
Qualifier
significant
NCT03355469_exc_T59
Qualifier
metabolic
NCT03355469_exc_T60
Qualifier
cardiac
NCT03355469_exc_T61
Condition
congestive heart failure
NCT03355469_exc_T62
Qualifier
cerebrovascular
NCT03355469_exc_T63
Qualifier
hematological
NCT03355469_exc_T64
Qualifier
pulmonary
NCT03355469_exc_T65
Qualifier
gastrointestinal
NCT03355469_exc_T66
Qualifier
liver
NCT03355469_exc_T67
Qualifier
renal
NCT03355469_exc_T68
Qualifier
endocrine
NCT03355469_exc_T69
Condition
disease
NCT03355469_exc_T70
Scope
metabolic, cardiac, congestive heart failure, cerebrovascular, hematological, pulmonary, gastrointestinal, liver, renal, or endocrine
NCT03355469_exc_T71
Condition
cancer
NCT03355469_exc_T73
Scope
 heart failure, cerebro  cancer that in 
NCT03355469_exc_T74
Condition
Pregnant
NCT03355469_exc_T75
Measurement
pregnancy test
NCT03355469_exc_T76
Value
positive
NCT03355469_exc_T77
Observation
nursing
NCT03355469_exc_T78
Person
women
NCT03355469_exc_T79
Condition
contraindications
NCT03355469_exc_T80
Observation
participation in an exercise training program
NCT03355469_exc_T81
Drug
active weight suppression medication
NCT03355469_exc_T82
Drug
phentermine
NCT03355469_exc_T83
Drug
orlistat
NCT03355469_exc_T84
Drug
lorcaserin
NCT03355469_exc_T85
Drug
naltrexone-bupropion in combination
NCT03355469_exc_T86
Drug
liraglutide
NCT03355469_exc_T87
Drug
benzephetamine
NCT03355469_exc_T88
Drug
diethylpropion
NCT03355469_exc_T89
Drug
phendimetrazine
NCT03355469_exc_T90
Scope
phentermine,orlistat, lorcaserin, naltrexone-bupropion in combination, liraglutide, benzephetamine, diethylpropion, phendimetrazine
NCT03355469_exc_T91
Condition
hypersensitivity
NCT03355469_exc_T92
Drug
perflutren
NCT03355469_exc_T93
Drug
Definity